The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogota

Mark J. M. Van Duin; Rafael Conde; Ben Wijnen; Silvia M. A. A. Evers; Javier L. Gonzalez-Rodriguez; Mark J. G. Govers; Mickal Hiligsmann

doi:10.1080/14737167.2017.1246185

The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogota

Mark J. M. Van Duin, Rafael Conde, Ben Wijnen, Silvia M. A. A. Evers, Javier L. Gonzalez-Rodriguez, Mark J. G. Govers, Mickal Hiligsmann^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

10 Citations (Web of Science)

Abstract

Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia.Methods: A cross-sectional study was conducted among 138 HIV patients at an outpatient clinic in Bogota to assess their costs, utilities (EQ5D-5L) and HRQOL (EQ-VAS). CMs and other covariates were gathered from patient records. Multiple regression models were conducted to assess the impact of CMs.Results: Of all patients, 72% experienced CMs; of these, half experienced 2 CMs (N=49). CMs had a statistically significant impact on utilities when the EQ5D-5L (P=0.022) was applied among patient with 2 CMs. No statistical significance was found for the impact of CMs on costs.Conclusion: This study suggests that having multiple CMs significantly influences utility, and CMs have some impact on HRQOL measured using the EQ-VAS but this effect is at the border of significance. No significant impact was observed on costs.

Original language	English
Pages (from-to)	303-310
Number of pages	8
Journal	Expert Review of Pharmacoeconomics & Outcomes Research
Volume	17
Issue number	3
DOIs	https://doi.org/10.1080/14737167.2017.1246185
Publication status	Published - 2017

Keywords

Human Immunodeficiency Virus (HIV)
Acquired Immune Deficiency Syndrome (AIDS)
burden of disease
healthcare costs
patient and family costs
utility
health-related quality of life (HRQOL)
bogota
Colombia
GLOBAL BURDEN
HIV/AIDS
DISEASE
DEPRESSION
AIDS
PREVALENCE
INFECTION
COLOMBIA
EXPENDITURES
INDIVIDUALS

Access to Document

10.1080/14737167.2017.1246185

Cite this

Van Duin, M. J. M., Conde, R., Wijnen, B., Evers, S. M. A. A., Gonzalez-Rodriguez, J. L., Govers, M. J. G., & Hiligsmann, M. (2017). The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogota. Expert Review of Pharmacoeconomics & Outcomes Research, 17(3), 303-310. https://doi.org/10.1080/14737167.2017.1246185

@article{1a51c5c3fd7c4006ac4a948f0dc8529f,

title = "The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogota",

abstract = "Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia.Methods: A cross-sectional study was conducted among 138 HIV patients at an outpatient clinic in Bogota to assess their costs, utilities (EQ5D-5L) and HRQOL (EQ-VAS). CMs and other covariates were gathered from patient records. Multiple regression models were conducted to assess the impact of CMs.Results: Of all patients, 72% experienced CMs; of these, half experienced 2 CMs (N=49). CMs had a statistically significant impact on utilities when the EQ5D-5L (P=0.022) was applied among patient with 2 CMs. No statistical significance was found for the impact of CMs on costs.Conclusion: This study suggests that having multiple CMs significantly influences utility, and CMs have some impact on HRQOL measured using the EQ-VAS but this effect is at the border of significance. No significant impact was observed on costs.",

keywords = "Human Immunodeficiency Virus (HIV), Acquired Immune Deficiency Syndrome (AIDS), burden of disease, healthcare costs, patient and family costs, utility, health-related quality of life (HRQOL), bogota, Colombia, GLOBAL BURDEN, HIV/AIDS, DISEASE, DEPRESSION, AIDS, PREVALENCE, INFECTION, COLOMBIA, EXPENDITURES, INDIVIDUALS",

author = "{Van Duin}, {Mark J. M.} and Rafael Conde and Ben Wijnen and Evers, {Silvia M. A. A.} and Gonzalez-Rodriguez, {Javier L.} and Govers, {Mark J. G.} and Mickal Hiligsmann",

year = "2017",

doi = "10.1080/14737167.2017.1246185",

language = "English",

volume = "17",

pages = "303--310",

journal = "Expert Review of Pharmacoeconomics & Outcomes Research",

issn = "1473-7167",

publisher = "Routledge/Taylor & Francis Group",

number = "3",

}

Van Duin, MJM, Conde, R, Wijnen, B , Evers, SMAA, Gonzalez-Rodriguez, JL, Govers, MJG & Hiligsmann, M 2017, 'The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogota', Expert Review of Pharmacoeconomics & Outcomes Research, vol. 17, no. 3, pp. 303-310. https://doi.org/10.1080/14737167.2017.1246185

TY - JOUR

T1 - The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogota

AU - Van Duin, Mark J. M.

AU - Conde, Rafael

AU - Wijnen, Ben

AU - Evers, Silvia M. A. A.

AU - Gonzalez-Rodriguez, Javier L.

AU - Govers, Mark J. G.

AU - Hiligsmann, Mickal

PY - 2017

Y1 - 2017

N2 - Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia.Methods: A cross-sectional study was conducted among 138 HIV patients at an outpatient clinic in Bogota to assess their costs, utilities (EQ5D-5L) and HRQOL (EQ-VAS). CMs and other covariates were gathered from patient records. Multiple regression models were conducted to assess the impact of CMs.Results: Of all patients, 72% experienced CMs; of these, half experienced 2 CMs (N=49). CMs had a statistically significant impact on utilities when the EQ5D-5L (P=0.022) was applied among patient with 2 CMs. No statistical significance was found for the impact of CMs on costs.Conclusion: This study suggests that having multiple CMs significantly influences utility, and CMs have some impact on HRQOL measured using the EQ-VAS but this effect is at the border of significance. No significant impact was observed on costs.

AB - Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia.Methods: A cross-sectional study was conducted among 138 HIV patients at an outpatient clinic in Bogota to assess their costs, utilities (EQ5D-5L) and HRQOL (EQ-VAS). CMs and other covariates were gathered from patient records. Multiple regression models were conducted to assess the impact of CMs.Results: Of all patients, 72% experienced CMs; of these, half experienced 2 CMs (N=49). CMs had a statistically significant impact on utilities when the EQ5D-5L (P=0.022) was applied among patient with 2 CMs. No statistical significance was found for the impact of CMs on costs.Conclusion: This study suggests that having multiple CMs significantly influences utility, and CMs have some impact on HRQOL measured using the EQ-VAS but this effect is at the border of significance. No significant impact was observed on costs.

KW - Human Immunodeficiency Virus (HIV)

KW - Acquired Immune Deficiency Syndrome (AIDS)

KW - burden of disease

KW - healthcare costs

KW - patient and family costs

KW - utility

KW - health-related quality of life (HRQOL)

KW - bogota

KW - Colombia

KW - GLOBAL BURDEN

KW - HIV/AIDS

KW - DISEASE

KW - DEPRESSION

KW - AIDS

KW - PREVALENCE

KW - INFECTION

KW - COLOMBIA

KW - EXPENDITURES

KW - INDIVIDUALS

U2 - 10.1080/14737167.2017.1246185

DO - 10.1080/14737167.2017.1246185

M3 - Article

C2 - 27730842

SN - 1473-7167

VL - 17

SP - 303

EP - 310

JO - Expert Review of Pharmacoeconomics & Outcomes Research

JF - Expert Review of Pharmacoeconomics & Outcomes Research

IS - 3

ER -